📊 MBIO Key Takeaways
Is Mustang Bio, Inc.. (MBIO) a Good Investment?
Mustang Bio is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial fundamentals. The company is burning approximately $5.3M annually in operating cash flow with zero revenue, making it entirely dependent on cash reserves and debt financing. With only 23 months of cash runway at current burn rates and a debt-to-equity ratio of 1.65x, the company faces significant solvency risk.
Mustang Bio remains a pre-revenue biotech with no commercial revenue base, negative operating cash flow, and ongoing losses, so the core fundamentals still depend on external financing or clinical/commercial execution. Losses improved materially year over year and liquidity is currently adequate, but leverage is high relative to equity and the business has not yet demonstrated durable revenue-generating capacity.
Why Buy Mustang Bio, Inc.. Stock? MBIO Key Strengths
- Adequate current liquidity ratio of 2.22x providing short-term operational buffer
- Relatively strong cash position of $17.3M enabling near-term development funding
- Positive operating income trend with net loss improving 87.8% YoY showing directional progress
- Net loss and diluted EPS improved significantly year over year
- Cash and equivalents of $17.27M support near-term liquidity
- Current and quick ratios of 2.22x indicate acceptable short-term balance sheet coverage
MBIO Stock Risks: Mustang Bio, Inc.. Investment Risks
- Zero revenue generation indicates no commercial viability or product commercialization success
- Negative operating cash flow of -$5.3M with negative free cash flow shows ongoing cash depletion
- Debt-to-equity ratio of 1.65x combined with negative interest coverage of -486.4x creates refinancing and solvency risk
- Pre-clinical stage company with no approved products limiting near-term revenue prospects
- Limited insider activity (1 Form 4 filing in 90 days) suggests minimal confidence from insiders
- Zero revenue means growth quality is weak and operations are not yet self-sustaining
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Debt-to-equity of 1.65x and deeply negative interest coverage reflect elevated financial risk
Key Metrics to Watch
- Monthly cash burn rate and runway remaining
- Progress on clinical trial milestones and regulatory filings
- Debt refinancing requirements and covenant compliance
- Operating cash flow trajectory toward sustainability
- Achievement of clinical development milestones
- Quarterly operating cash burn relative to cash balance
- Any transition from zero revenue to recurring product or collaboration revenue
Mustang Bio, Inc.. (MBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.22x current ratio provides a solid financial cushion.
MBIO Profit Margin, ROE & Profitability Analysis
MBIO vs Healthcare Sector: How Mustang Bio, Inc.. Compares
How Mustang Bio, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mustang Bio, Inc.. Stock Overvalued? MBIO Valuation Analysis 2026
Based on fundamental analysis, Mustang Bio, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mustang Bio, Inc.. Balance Sheet: MBIO Debt, Cash & Liquidity
MBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mustang Bio, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-38.57 indicates the company is currently unprofitable.
MBIO Revenue Growth, EPS Growth & YoY Performance
Mustang Bio, Inc.. Dividends, Buybacks & Capital Allocation
MBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mustang Bio, Inc.. (CIK: 0001680048)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBIO
What is the AI rating for MBIO?
Mustang Bio, Inc.. (MBIO) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBIO's key strengths?
Claude: Adequate current liquidity ratio of 2.22x providing short-term operational buffer. Relatively strong cash position of $17.3M enabling near-term development funding. ChatGPT: Net loss and diluted EPS improved significantly year over year. Cash and equivalents of $17.27M support near-term liquidity.
What are the risks of investing in MBIO?
Claude: Zero revenue generation indicates no commercial viability or product commercialization success. Negative operating cash flow of -$5.3M with negative free cash flow shows ongoing cash depletion. ChatGPT: Zero revenue means growth quality is weak and operations are not yet self-sustaining. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is MBIO's revenue and growth?
Mustang Bio, Inc.. reported revenue of $0.0.
Does MBIO pay dividends?
Mustang Bio, Inc.. does not currently pay dividends.
Where can I find MBIO SEC filings?
Official SEC filings for Mustang Bio, Inc.. (CIK: 0001680048) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBIO's EPS?
Mustang Bio, Inc.. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Mustang Bio, Inc.. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBIO stock overvalued or undervalued?
Valuation metrics for MBIO: ROE of -20.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBIO stock in 2026?
Our dual AI analysis gives Mustang Bio, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBIO's free cash flow?
Mustang Bio, Inc..'s operating cash flow is $-5.3M, with capital expenditures of $0.0.
How does MBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -20.2% (avg: 15%), current ratio 2.22 (avg: 2).
Is Mustang Bio, Inc.. carrying too much debt?
MBIO has a debt-to-equity ratio of 1.65x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.22 suggests adequate short-term liquidity.